Cogent Biosciences Awaits FDA Decision on Bezuclastinib for Systemic Mastocytosis
Cogent Biosciences has submitted a New Drug Application for bezuclastinib to treat systemic mastocytosis caused by the KIT D816V mutation, with FDA review underway and strong analyst support.
Cogent Biosciences announced FDA acceptance of its New Drug Application for bezuclastinib in non-advanced systemic mastocytosis. The clinical-stage biotechnology company is awaiting regulatory approval for its flagship product.
Bezuclastinib is currently in a Phase 3 trial aimed at addressing the KIT D816V mutation that causes systemic mastocytosis, among other mutations. The company focuses on precision therapies for genetically defined diseases.
The company boasts 11 buy ratings, supplemented by 2 hold ratings and no sell ratings, indicating strong bullish sentiment among market analysts. The average target price of $53.83 suggests a potential upside of 40.41% from its current trading price of $38.34 per share.
With a market capitalization of $5.89 billion, Cogent is headquartered in Waltham, Massachusetts. Over the past 52 weeks, the stock has experienced a range between $4.02 and $42.11.
The company's innovative pipeline includes other promising candidates such as CGT4859, a selective fibroblast growth factor receptor 2 inhibitor, and CGT6297, a novel PI3Ka mutant-selective inhibitor. The company has a licensing agreement with Plexxikon Inc.
The forward P/E ratio of -62.39 and negative EPS of -2.05 highlight the company's ongoing investment in research and development, typical of a company at this stage without significant revenue streams. The company's free cash flow is reported at -$152,490,624, and its return on equity stands at -73.70%. The company does not pay dividends, with a payout ratio of 0.00%.